MULTIPLE MYELOMA

Latest News

CAR T and CRS Adverse Events Considered in Relapsed Multiple Myeloma
CAR T and CRS Adverse Events Considered in Relapsed Multiple Myeloma

October 24th 2024

During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed CAR T-cell therapy as third-line therapy for a patient with relapsed/refractory multiple myeloma and relevance of the KarMMa-3 trial for their treatment.

Roundtable Roundup: Early-Line Use of CAR T-cell Therapy in Multiple Myeloma
Roundtable Roundup: Early-Line Use of CAR T-cell Therapy in Multiple Myeloma

October 22nd 2024

Teclistamab Shows 100% Response Rate in High-Risk Smoldering Myeloma
Teclistamab Shows 100% Response Rate in High-Risk Smoldering Myeloma

October 15th 2024

Bringing Bispecific Antibody Therapy to Community Oncology Centers
Bringing Bispecific Antibody Therapy to Community Oncology Centers

October 11th 2024

Functional High Risk and Bridging in Multiple Myeloma Considered With CAR T Cells
Functional High Risk and Bridging in Multiple Myeloma Considered With CAR T Cells

October 9th 2024

Video Series
Video Interviews
Podcasts

More News